Skip to main content
Clinical Trials/CTRI/2024/03/064161
CTRI/2024/03/064161
Not yet recruiting
Phase 4

Comparative study to evaluate efficacy and safety of topical alcaftadine 0.25% versus topical olopatadine 0.2% eye drops in patients with allergic conjunctivits in a tertiary care teaching hospital, Haldwani - NI

eeraj Rajdan0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: H109- Unspecified conjunctivitis
Sponsor
eeraj Rajdan
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
eeraj Rajdan

Eligibility Criteria

Inclusion Criteria

  • Patient aged 5\-20 years of age with history of allergic conjunctivitis presenting to OPD will be enrolled

Exclusion Criteria

  • Subjects undergone any ocular surgical intervention within three months
  • Patients on steroid therapy, immunotherapeutic agents
  • Patients using other topical eye drops (ocular lubricants)
  • Patients used any investigational medication within one month of the study
  • Patients with known hypersensitivity to Olopatadine \& Alcaftadine
  • Pregnant and lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials